Journal decision profile

Progress in Neuro-Psychopharmacology & Biological Psychiatry

Medicine · Neuroscience

Progress in Neuro-Psychopharmacology & Biological Psychiatry's 2026 Journal Metrics Score is 3.5, ranking Q1 in Psychiatry and Mental health. Two-year citation average from OpenAlex data, updated August 2026.

Elsevier BVUnited StatespISSN 0278-5846eISSN 1878-4216
Checking system sharing availability.Visit homepage

Bookmark this page — track observed submission-to-acceptance timing, FWCI and field-normalized citation data for this journal in one view.

Journal Metrics Score
i
Journal Metrics ScoreThe raw score is citations received in the latest complete year by works from the two previous years, divided by the number of those works. It is calculated from OpenAlex open data (CC0) and is not a percentage grade.
2026
3.5

Journal Metrics Score 2026 · 2021–2024 window citedness 5.07.

Review & acceptance time
i
Review & acceptance timeCalendar days between the received and accepted dates reported in recent PubMed records. This interval includes editorial handling and author revisions, so it is not time to first decision or pure peer-review time.
PUBMED
173 daysmedian

Middle 50%: 144–220 days

99 of 100 PubMed-indexed articles · 99% coverage · 2024–2025

Progress in Neuro-Psychopharmacology & Biological Psychiatry accepts papers a median of 173 days after submission, including peer review and revisions. That is slower than 84% of comparable journals with PubMed timing data.

Indicative APC
i
Indicative APCThis journal-level estimate comes from the OpenAlex source record. It is not a verified quote and may exclude taxes, waivers, society discounts, or article-type charges. Check the journal's official website before deciding.
OPENALEX · VERIFY
$3,720

Journal-level estimate only. Verify current charges, taxes, waivers, discounts, and article-type fees with the journal.

Free preview · no sign-in

Does your manuscript fit Progress in Neuro-Psychopharmacology & Biological Psychiatry?

Paste your title to see which of this journal's published topics it overlaps with. Your title stays in your browser for this preview and is not sent anywhere.

Want ranked journals with fit reasons, risks and a submission strategy instead? See a sample AI report.

At a glance

Journal decision profile

Each spoke is a 0–100 percentile within a comparable journal cohort—not a percentage grade or a single black-box rating.

Relative profile

Metrics ScoreThe raw 2026 Journal Metrics Score is the recent two-year citation average shown above. The radar converts it to a 0–100 cohort percentile: farther out means a higher score than more comparable journals. It is not a percentage grade.iSource outputThe raw rank compares lifetime output inside the journal’s leading-topic source set. The radar then compares that rank position across Decision Profile journals in the same primary OpenAlex field; when that field has too few profiles, it uses the broader profile set. Farther out means relatively more output, not better research quality.iTop 10% shareThe share of recent papers in the global top 10% for citations after comparing papers of the same type, publication year, and subfield. The radar converts that share to a 0–100 cohort percentile; it does not predict how a new paper will perform.iMedian FWCICitation performance of the middle recent paper after field, year, and work type are considered. A raw FWCI of 1.0 is the expected citation level for comparable papers; the radar shows its 0–100 cohort percentile.iSubmission-to-acceptanceCalendar days from the received date to the accepted date in recent PubMed records. This includes editorial handling and author revisions, so it is not the time to first decision and not pure peer-review time. The radar uses a 0–100 cohort percentile with shorter observed timing plotted farther out; it does not measure review quality.iOutput volumeAverage works published per year in the recent analysis window, converted to a 0–100 cohort percentile. Farther out means the journal publishes more papers; it does not mean those papers are better.i
Cost is intentionally excluded. Missing APC data is never converted to a zero-dollar fee or a fabricated cost score.

Raw values behind the shape

Always visible
Metrics Score
i
Metrics ScoreThe 2026 raw Journal Metrics Score shown above. The bar is its 0–100 percentile within the radar's comparable journal cohort; it is not a percentage score.
3.52026 · OPENALEX
Source output rank
i
Source output rankThis lifetime journal-wide output rank compares works published by the OpenAlex source with sources associated with the journal’s leading topic. More output does not mean higher quality.
#64 / 1,089LIFETIME OUTPUT
Highly cited papers
i
Highly cited papersShare of recent works in the global top 10% for citations after comparing papers of the same type, publication year, and subfield.
22.7%FIELD-NORMALIZED TOP 10%
Field-normalized impact
i
Field-normalized impactCitation performance of the middle recent paper after field, year, and work type are considered. A raw FWCI of 1.0 is the expected level for comparable work.
1.27MEDIAN FWCI
Submission-to-acceptance
i
Submission-to-acceptanceReceived-to-accepted calendar days from qualified PubMed records. It includes editorial handling and author revisions; it is not time to first decision or pure peer-review time.
173 daysIQR 144–220 DAYS
Recent output
i
Recent outputAverage works published per year across the complete analysis window. This is a volume measure, not a quality score.
205 / yr2021–2024 AVG
Field-normalized top 10% share22.7%

186 of 820 works · same type, year & subfield

Field-normalized top 1% share1.6%

13 works · same type, year & subfield

Median FWCI1.27×

Above field-year expectation

Source output rank#64

of 1,089 topic-associated OpenAlex sources by lifetime output

What does Median FWCI mean?

FWCI compares papers with the same publication year, type, and field. 1.0 is the world average; above 1.0 is above expectation. This journal's median is 1.27, so its typical recent paper runs about 27% above its field benchmark.

What does Top 10% Share mean?

22.7% of recent papers rank in the global top 10% after field normalization. This is easier to compare across specialties than raw citation totals.

Publishing pattern

Publication volume and article mix

Volume is separated from citation accumulation so newer papers are not presented as weaker simply because they are newer.

Works published by year

OpenAlex source records · 2016–2025

1312016
3312017
2682018
2412019
3232020
2132021
1552022
1752023
2772024
3322025

Recent work-type mix

820 OpenAlex works · 2021–2024

Article86.3%
Review9.4%
Paratext3.5%
Erratum0.4%
Editorial0.2%
Letter0.1%
OpenAlex article is broader than “original research.” PubMed Publication Types can add case-report and clinical-study detail.
Fit signals

Topics and medical subject coverage

OpenAlex topics show research communities; MeSH keeps the medical taxonomy recognizable.

Major MeSH signals

PubMed-indexed works

Select a MeSH signal to see how much Progress in Neuro-Psychopharmacology & Biological Psychiatry publishes on it, from PubMed counts for the last five complete years.

Leading OpenAlex topics

2021–2024 works
Tryptophan and brain disorders72
Functional Brain Connectivity Studies51
Schizophrenia research and treatment40
Cannabis and Cannabinoid Research36
Stress Responses and Cortisol33
Diverse Scientific and Economic Studies29
Zebrafish Biomedical Research Applications29
Neurotransmitter Receptor Influence on Behavior27
Neuroscience and Neuropharmacology Research26
Treatment of Major Depression21
Methodology: OpenAlex snapshot 2026-08-12. FWCI, percentile badges, topics, and type mix use 820 works published 2021–2024. Radar normalization is versioned in the cached profile, and no cost score is assigned without reliable APC data.

Subject Category Quartiles

Quartiles computed within each OpenAlex subfield
CategoryQuartile
Cellular and Molecular NeuroscienceQ2
Biological PsychiatryQ2
Psychiatry and Mental healthQ1

Is Progress in Neuro-Psychopharmacology & Biological Psychiatry a good journal?

Yes. A Q1 journal by citation data

Yes. By citation data, Progress in Neuro-Psychopharmacology & Biological Psychiatry is a strong journal: it is Q1 in Psychiatry and Mental health and ranks #285 of 2,466 Psychology journals by Journal Metrics Score (top 12%). Progress in Neuro-Psychopharmacology & Biological Psychiatry's 2026 Journal Metrics Score is 3.5. Recent papers took a median of 173 days from submission to acceptance, according to PubMed dates. OpenAlex lists an indicative article processing charge of $3,720 USD. OpenAlex classifies its papers in subfields including Cellular and Molecular Neuroscience, Biological Psychiatry, and Psychiatry and Mental health, so check that your topic fits its scope.

Best quartile
Q1
Psychiatry and Mental health
Rank in Psychology
#285 of 2,466
Top 12%
2026 Journal Metrics Score
3.5
Acceptance rate
Not published
By the journal or publisher
Submission to acceptance
173 days
Median, PubMed records
Indicative APC
$3,720
OpenAlex, verify with the journal
Papers published in 2025
332
OpenAlex works

Check before you submit

  • Its output more than doubled, from 155 papers in 2022 to 332 in 2025. Fast-growing journals can change in scope and editorial standards, so read recent papers in your topic.
  • Confirm the current article processing charge, waivers, and any institutional agreement on the journal website; the OpenAlex figure is indicative.
  • Confirm the journal is indexed where your institution or funder requires (for example Scopus or PubMed) before you submit.

Verdict from citation data only: quartile and field rank by Journal Metrics Score (OpenAlex), publisher-reported acceptance rates, and PubMed submission and acceptance dates. See how we rank journals and how to verify indexing.

Q1
Subfield Quartile
B2
CAS Block

Ranking and source check

#285
of 2,466 Psychology field journals
#284
among Q1 Psychology journals

Confirm the exact title and ISSNs against the publisher homepage before a high-stakes submission decision.

Journal Details

OpenAlex Works
8,323
H-Index
188
Fully Open Access
No
Recent OA Works
1,279
Subject Areas
Cellular and Molecular NeuroscienceBiological PsychiatryPsychiatry and Mental health

Source: the current OpenAlex source record. OpenAlex works can include multiple work types. Fully Open Access is a source-level flag. Recent OA Works is summed from OpenAlex's counts_by_year series (up to the latest ten years); it is not a lifetime OA percentage. Any APC shown here is an indicative OpenAlex value—verify current charges on the journal's official website.

How to submit to Progress in Neuro-Psychopharmacology & Biological Psychiatry

  1. 1

    Check the scope

    OpenAlex classifies Progress in Neuro-Psychopharmacology & Biological Psychiatry's papers in subfields including Cellular and Molecular Neuroscience, Biological Psychiatry, and Psychiatry and Mental health. Read the aims and scope page and a few recent papers close to your topic before you prepare the manuscript.

  2. 2

    Follow the author guidelines

    Article types, word and figure limits, reference style, and the required statements (data availability, ethics, conflicts of interest, author contributions) are set by the journal. Prepare the cover letter and files to match them.

    Progress in Neuro-Psychopharmacology & Biological Psychiatry homepage ↗
  3. 3

    Submit through Editorial Manager

    Most Elsevier and Cell Press journals take submissions through Editorial Manager; each journal has its own site, reached from Submit your article on the journal homepage.

  4. 4

    Plan for costs

    OpenAlex lists an indicative article processing charge of $3,720 USD. Check the current fee, waivers, and any institutional agreement on the journal website.

  5. 5

    Know what to expect

    Recent accepted papers took a median of 173 days from submission to acceptance, including revisions (PubMed dates). Progress in Neuro-Psychopharmacology & Biological Psychiatry does not publish an acceptance rate.

Submission system from the publisher's author information, checked 2026-10-27. Individual journals can differ, so follow the link in the journal's own author guidelines.

New on PubMed

What's new in your field?

Type a topic to see the newest PubMed papers from the past week and the big picture of what they found, summarized by Claude on the Pro plan. Get a free weekly email to keep up.

See a demo:GLP-1CRISPRLong COVID

Reviewer Two · coming soon

Know what reviewers will say before you submit to Progress in Neuro-Psychopharmacology & Biological Psychiatry

An AI pre-submission report on your manuscript: the objections a tough reviewer is likely to raise, desk-rejection risks, and better-fit journals from our data. $29 per report.

See what the report covers

Common questions about Progress in Neuro-Psychopharmacology & Biological Psychiatry

Is Progress in Neuro-Psychopharmacology & Biological Psychiatry a good journal?

Yes. By citation data, Progress in Neuro-Psychopharmacology & Biological Psychiatry is a strong journal: it is Q1 in Psychiatry and Mental health and ranks #285 of 2,466 Psychology journals by Journal Metrics Score (top 12%). Progress in Neuro-Psychopharmacology & Biological Psychiatry's 2026 Journal Metrics Score is 3.5. Recent papers took a median of 173 days from submission to acceptance, according to PubMed dates. OpenAlex lists an indicative article processing charge of $3,720 USD. OpenAlex classifies its papers in subfields including Cellular and Molecular Neuroscience, Biological Psychiatry, and Psychiatry and Mental health, so check that your topic fits its scope.

What is Progress in Neuro-Psychopharmacology & Biological Psychiatry's Journal Metrics Score in 2026?

Progress in Neuro-Psychopharmacology & Biological Psychiatry's 2026 Journal Metrics Score is 3.5, from the August 2026 data release. The score is a two-year citation average computed from OpenAlex (CC0) data: citations received in the most recent complete year to works published in the two prior years, divided by the number of those works.

What is the acceptance rate of Progress in Neuro-Psychopharmacology & Biological Psychiatry?

We have not found an official acceptance rate published by Progress in Neuro-Psychopharmacology & Biological Psychiatry or its publisher, and Journal Metrics does not estimate one because submission counts are not public. What recent PubMed records do show is speed: accepted papers took a median of 173 days from submission to acceptance. To judge selectivity, compare Progress in Neuro-Psychopharmacology & Biological Psychiatry's quartile and score with similar journals, or ask the editorial office.

What quartile is Progress in Neuro-Psychopharmacology & Biological Psychiatry in?

Progress in Neuro-Psychopharmacology & Biological Psychiatry's best quartile is Q1. By OpenAlex subfield: Q2 in Cellular and Molecular Neuroscience; Q2 in Biological Psychiatry; Q1 in Psychiatry and Mental health. Quartiles rank journals by Journal Metrics Score within each subfield.

Is the Journal Metrics Score the same as other journal citation metrics?

No. Journal Metrics computes the score independently from OpenAlex open data. Other providers use different citation databases, document types, and counting rules, so their published figures for Progress in Neuro-Psychopharmacology & Biological Psychiatry will not match this score exactly. Compare journals using one source at a time.

How long does Progress in Neuro-Psychopharmacology & Biological Psychiatry take to accept a paper?

Progress in Neuro-Psychopharmacology & Biological Psychiatry accepts papers a median of 173 days after submission across 99 recent PubMed records with both dates; the middle half took 144–220 days. This includes peer review, editorial handling, and revisions.

How long is the peer review time at Progress in Neuro-Psychopharmacology & Biological Psychiatry?

PubMed records when a manuscript was received and accepted, not the individual review stages, so peer review time on its own is not available. The full time from submission to acceptance at Progress in Neuro-Psychopharmacology & Biological Psychiatry, which includes peer review and revisions, has a median of 173 days. For the time to a first decision, check the journal's own website.

Is Progress in Neuro-Psychopharmacology & Biological Psychiatry faster than similar journals?

Progress in Neuro-Psychopharmacology & Biological Psychiatry's median of 173 days from submission to acceptance is slower than 84% of comparable journals with PubMed timing data.

How much does it cost to publish in Progress in Neuro-Psychopharmacology & Biological Psychiatry?

OpenAlex lists an indicative article processing charge of $3,720 USD for Progress in Neuro-Psychopharmacology & Biological Psychiatry. This journal-level estimate may exclude taxes, waivers, discounts, or article-type fees, so confirm the current charge on the journal's website.

Which journals are alternatives to Progress in Neuro-Psychopharmacology & Biological Psychiatry?

Comparable journals include Neuropsychopharmacology, Behavioural Brain Research, Biological Psychiatry: Global Open Science, and Biological Psychiatry. Compare their scores, acceptance times, and costs in the recommended alternatives on this page before choosing where to submit.

How do I submit a paper to Progress in Neuro-Psychopharmacology & Biological Psychiatry?

Most Elsevier and Cell Press journals take submissions through Editorial Manager; each journal has its own site, reached from Submit your article on the journal homepage. Before submitting, check the scope, follow the author guidelines for article type, length, and required statements, and prepare a cover letter. Accepted papers took a median of 173 days from submission to acceptance in recent PubMed records.

Cite an article from this journal
Back to Search